Tscan Therapeutics, Inc. Stock Price, News & Analysis

TScan Therapeutics, Inc. (Nasdaq: TCRX) will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 12:55 p.m. ET in New York, NY. The event will be webcasted, and an archived replay will be available on the company’s website for 30 days. TScan focuses on T cell receptor (TCR) engineered therapies for cancer, with lead candidates TSC-100 and TSC-101 targeting hematologic malignancies. Their ImmunoBank aids in developing customized therapies for various solid tumors.

TScan Therapeutics, Inc. (TCRX) reported its Q2 2022 results, highlighting a revenue increase to $4.1 million from $2.8 million last year, driven by its collaboration with Novartis. The company ended the quarter with $125.6 million in cash, sufficient to fund operations into 2024. The Phase 1 trial for TCR therapies TSC-100 and TSC-101 is now open for enrollment. TScan anticipates IND filings for TSC-200-A2 and TSC-204-C7 by the end of 2022. However, net losses rose to $15.1 million from $10.7 million in the prior year.

TScan Therapeutics, Inc. (Nasdaq: TCRX), a company focused on T cell receptor (TCR) engineered therapies for cancer, will have its CEO, David P. Southwell, participate in a virtual panel at the 13th Annual Wedbush PacGrow Healthcare Conference on August 10, 2022, at 1:10 p.m. ET. This discussion titled “A View to a Kill(er Cell)” will delve into advancements in TCR-T therapies. A webcast of the panel will be available on TScan's website, along with an archived replay for 30 days after the event.

The company is developing TCR-T therapies aimed at hematologic malignancies and solid tumors.

TScan Therapeutics (Nasdaq: TCRX) announced the publication of a peer-reviewed article in Cell, showcasing its screening technology that identifies T cell targets in head and neck cancer patients undergoing immunotherapy. The study revealed the TCR engineered candidate TSC-204-C07 targeting MAGE-A1. The research involved 29 patients and was a collaboration with Harvard institutions. TScan aims to file an IND for TSC-204-C07 in late 2022, alongside plans to develop multiplexed TCR therapies for solid tumors. The company positions itself for growth in TCR-T therapies.

TScan Therapeutics, Inc. (TCRX) has appointed Dr. Debora Barton as Chief Medical Officer, bringing nearly 20 years of clinical oncology experience. This appointment coincides with the upcoming Phase 1 trial for leukemia therapy, aimed at treating hematologic malignancies. Dr. Barton previously held key roles at Carisma Therapeutics and Iovance Biotherapeutics, overseeing clinical development and operations. TScan is focused on T-cell receptor engineered therapies, with lead candidates in development targeting both liquid and solid tumors.

TScan Therapeutics, Inc. (Nasdaq: TCRX) announced its participation in a virtual fireside chat at the LifeSci 2nd Annual Genetic Medicines Symposium on June 28, 2022, at 9:00 a.m. ET. The event will focus on T-cell receptor (TCR) engineered therapies aimed at treating cancer. Interested parties can access a live webcast via the company’s website, with an archived replay available for 30 days post-event. TScan specializes in innovative TCR-T therapies, including candidates TSC-100 and TSC-101 targeting hematologic malignancies.

TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biopharmaceutical company, will participate in a fireside chat at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 9:30 a.m. ET in New York. This event will focus on TCR engineered T cell therapies for cancer treatment. Interested parties can access the live webcast on the Company's website, with an archived replay available for 30 days post-event. TScan's lead therapies, TSC-100 and TSC-101, aim to treat hematologic malignancies and prevent leukemia relapse post-transplant.

TScan Therapeutics has announced the initiation of study start-up activities for its Phase 1 clinical trial involving TSC-100 and TSC-101, following FDA clearance of the investigational new drug (IND) application for TSC-101 targeting hematologic malignancies. This marks the second IND clearance for TScan’s leukemia program, aimed at reducing relapse risks after allogeneic hematopoietic cell transplantation. Preliminary data from the three arms of the trial are expected by the end of 2022.

TScan Therapeutics (TCRX) has identified its lead TCR-T cell therapy candidate, TCR-200-A02, for HPV-positive solid tumors, with an IND submission expected in 2H22. Additionally, TCR-204-C07 targets a novel MAGEA1 epitope, also on track for IND submission. Preclinical results show TCR-200-A02 exhibits strong cytotoxicity against HPV+ cell lines and no off-target activity. The multiplexing of TCRs demonstrates potential for enhanced anti-tumor effectiveness, overcoming tumor antigen heterogeneity. TScan will present further data at a virtual KOL event on May 19, 2022.